Europe Parenteral Lipid Emulsion Market Size, Share & Trends Analysis Report By Ingredient (1st Generation Lipid Emulsions, 2nd Generation Lipid Emulsions, 3rd Generation Lipid Emulsions), By Country, And Segment Forecasts, 2023 - 2030

Report Overview

The Europe parenteral lipid emulsion market size was worth USD 640.9 million in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 6.3% from 2023 to 2030. Growing incidence of hospital malnutrition, the rising prevalence of cancer, gastrointestinal disorders, and other chronic disorders are some of the major factors contributing to the market growth.  Hospital malnutrition is a significant concern in hospitals across Europe.It can lead to a range of negative outcomes, such as longer hospital stays, increased risk of complications, and higher mortality rates. According to Specialized Nutrition Europe, 40% of adult hospital patients in the EU are malnourished. The economic burden of malnourishment is estimated at USD 136.8 billion (EUR 120 billion) across Europe.Furthermore, as per the National Library of Medicine, recent publications on hospital malnutrition in Europe reveal that the incidence and prevalence of malnutrition remain alarmingly high at 21% and 37%, respectively.

Furthermore, the rising geriatric population is boosting the demand for parenteral lipid emulsion.According to several NCBI studies, individuals aged over 65 years are at a greater risk of developing chronic illnesses such as Parkinson’s and nervous system disorders.The risk of malnutrition and frailty among the geriatric population with comorbidities, such as stroke, depression, and dementia, is much higher, mainly owing to various age-related changes in body composition and muscle mass. This results in a reduced ability to perform Activities of Daily Living (ADLs), thereby increasing the risk of falls or injuries. Also, the incidence of Alzheimer’s disease is constantly rising due to the increase in the number of people aged 65 and above in Europe. According to ScienceDirect research estimates, the prevalence of Alzheimer's disease in Europe is 5.05%, with a higher prevalence observed in women (7.13%) than in men (3.31%). The prevalence of Alzheimer's disease also increases with age.Thus, the rapid rise in the elderly population and increase in the prevalence of age-related chronic diseases and medical conditions are factors expected to contribute to the growth of the market.

Gastrointestinal disorder is another major factor impelling the demand for parenteral lipid emulsion.Gastrointestinal disease significantly impacts a patient's ability to absorb nutrients from food, resulting in malnutrition and other complications. In cases where the patient is unable to consume food orally, parenteral nutrition may be necessary to meet their nutritional needs.Lipid emulsions are a type of parenteral nutrition that can be used to provide a source of essential fatty acids and calories. This can be especially beneficial for patients with severe gastrointestinal diseases, such as inflammatory bowel disease, pancreatitis, or intestinal obstruction, who are unable to absorb nutrients from food or tolerate enteral nutrition.

In addition, the rising prevalence of cancer is boosting the demand for parenteral lipid emulsion. The European continent recorded approximately four million new cases of cancer in 2020, with an estimated 1.9 million fatalities attributed to the disease. This figure is consistent with the estimates from 2018.The prevalence of cancer varies among European countries, with some countries having higher rates than others. For example, according to the latest available data, the highest cancer incidence rates in Europe are found in Denmark, Belgium, and the Netherlands, while the lowest rates are found in countries such as Albania, Macedonia, and Bosnia and Herzegovina. As per the European Society for Medical Oncology new research published in Annals of Oncology, a prominent cancer journal, has projected that in 2023, the number of cancer-related deaths in the EU-27 is likely to be 1,261,990, while in the UK, it is estimated to be 172,314.Cancer generally leads to stomach ulcers and disorientation in the normal functioning of the gastrointestinal tract and the development of physical obstructions, leading to the need for parenteral lipid emulsions, which are essential components of PN.

The COVID-19 pandemic had a significant impact on the healthcare industry, including the market for parenteral lipid emulsion. Critically ill patients, particularly those who tested positive for COVID-19, were highly sensitive and required specialized care. COVID-19 had weakened a patient's immune system and caused respiratory and other system disruptions. For instance, according to an article published in Elsevier Public Health Emergency Collection, around half of the critically ill COVID-19 patients developed gastrointestinal problems such as gastrointestinal hypomotility. In addition, patients experienced various other abdominal problems, leading to an increase in the adoption of PN at global and country levels.In addition, several studies justified the use of PN for patients suffering from malnutrition problems that increased during the pandemic, leading to market growth. For instance, according to an article published in the Journal of the Academy of Nutrition and Dietetics, many patients admitted to the ICU for COVID-19 treatment suffered from acute malnourishment. Hence, the usage of PN products increased in the market during the pandemic.

Ingredient Insights

The 1^st generation parenteral lipid emulsion segment dominated the market with a 36.3% share in 2022 owing to the increasing geriatric population and the growing burden of non-communicable diseases on healthcare. The 1^st generation products include soybean-based lipid emulsions, which can significantly reduce dependence on dextrose (major source of nonprotein calories) in parenteral nutrition. In addition, these formulations have been a go-to product for decades among malnourished patients of all age groups when the enteral feeding route is inhibited, insufficient, or impossible.

However, the 3^rd generation is expected to grow at the fastest rate of 7.4% over the forecast period owing to the increasing administration of fish oil parenteral lipid emulsions. This is due to the availability of EPA and DHA, which offer demonstrable effects on inflammatory processes and cell membranes and help decrease the length of stay among critically ill patients. In addition, the administration of fish oil-enriched parenteral nutrition formulations is increasing among patients undergoing major surgical procedures to help lower postoperative inflammatory response. For instance, suppression of proinflammatory cytokine IL-6 has been reported following parenteral fish oil administration in elderly patients undergoing hip surgery when compared to the absence of intravenous fish oil administration. This, in turn, is driving demand for fish oil lipid emulsions, thereby, aiding market growth.

Country Insights

Germany held the largest market share of 24.1% in 2022.Germany has a high-quality healthcare infrastructure. The increasing adoption of lipid emulsions, owing to their high caloric content and concentrated source of energy, is driving the market in the country. An increase in the demand from critically ill patients and high prevalence of chronic diseases, including diabetes, cancer, and inflammatory bowel disease, are among the key factors expected to drive adoption in hospitals.According to the International Diabetes Federation Diabetes Atlas 2021, around 6,199,900 individuals aged between 20 and 79 in Germany were suffering from cancer.

Furthermore, the country is expected to grow at the fastest rate due to increasing government investments owing to growing public finances, robust institutional framework, and rising competitiveness among various global and domestic players of parenteral lipid emulsion. Also, technological advancements in medical research equipment, and growing demand for continuous care services are some of the key factors expected to drive the parenteral nutrition market over the forecast period.

Key Companies & Market Share Insights

Key players are adopting several strategic initiatives to strengthen their market position, including mergers and acquisitions, partnerships, collaborations, and developing and introducing cutting-edge products. For instance, in August 2019, In August 2019, Baxter announced the launch of Olimel N12 in the European market. The launch is a new addition to the company’s olive oil-based parenteral nutrition (PN) triple chamber bag portfolio. Similarly, in January 2020, Fresenius Kabi completed its clinical trial for SmofKabiven. SmofKabiven is their new launch in the range of lipid emulsions. It is made up of multiple oils (fish oil, soybean oil, olive oil, and medium-chain triglycerides) along with a separate chamber for amino acids, glucose, and lipids. Some prominent players in the Europe parenteral lipid emulsion market include:

• Baxter

• Braun Melsungen AG

• Fresenius SE & Co. KGaA

• Grifols S.A.

Europe Parenteral Lipid Emulsion Market Report Scope

Europe Parenteral Lipid Emulsion Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research, Inc. has segmented the Europe parenteral lipid emulsion market report on the basis of ingredient, and country:

• Ingredient Outlook (Revenue, USD Million, 2018 - 2030)

  • 1^st Generation Lipid Emulsions

  • 2^nd Generation Lipid Emulsions

  • 3^rd Generation Lipid Emulsions

• Country Outlook (Revenue, USD Million, 2018 - 2030)

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Austria

    • Belgium

    • Ireland

    • Poland

    • Czech Republic